中文摘要：

目的 调查乳腺癌患者焦虑发生情况,探讨表面增强激光解吸电离飞行时间质谱（SELDI-TOF-MS,简称SELDI）技术在焦虑评估中的临床应用价值.方法 采用便利抽样法选取121例乳腺癌患者作为研究对象,入院当日应用焦虑自评量表（SAS）对其进行评估,征得患者同意后,于次日清晨抽取患者空腹静脉血,应用SELDI技术检测血清,筛选焦虑相关蛋白质指纹图谱.分析比较SELDI检测结果与SAS量表评分.结果 121例乳腺癌患者的SAS评分为（53.45±9.78）分,发生焦虑患者63例（52.07％）.以质荷比15000＋H- 16800＋H之间5％蛋白质指纹丰度建立诊断模型,即以SELDI检测蛋白质指纹丰度值≥5％判断为阳性,反之为阴性,在此基础上准确将乳腺癌患者分为焦虑组与非焦虑组.SELDI正确率（总符合率）为91.74％,特异度和灵敏度分别为89.66％（52/58）、93.65％（59/63）,阳性预测值为90.77％（59/65）,阴性预测值为92.86％（52/56）.结论 乳腺癌患者焦虑发生率较高.SELDI技术在焦虑情绪的评估方面表现出较高的灵敏性和特异性,作为一种客观的评估手段,具有较好的临床运用前景。

英文摘要：

Objective To investigate the incidence of anxiety in patients with breast cancer,and further explore the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry （SELDI） technology＆#39; s clinical value in the diagnosis of anxiety.Methods 121 breast cancer patients were selected as research objects by using convenience sampling method.Self-rating anxiety scale （SAS） was used to evaluate the anxiety on the first day of admission and SELDI was used on the next day to detect the serum from patients＆#39; fasting venous blood sample got in the morning after their consent,then anxiety-related protein fingerprints spectrums were selected.The SAS score and SELDI result were finally compared and analyzed.Results SAS score in 121 patients was 53.45±9.78,anxiety occurred in 63 cases （52.07 %）.Established the diagnostic model between 15 000＋H and 16 800＋H protein fingerprints abundance ≥5 %,that was to say,abundance ≥5 % was judged as positive,otherwise negative.On this basis,patients can accurately be distinguished between anxious group and non-anxious group.Correct rate （total coincidence rate） was 91.74 %,specificity and sensitivity respectively were 89.66 % （52/58） and 93.65 % （59/63）,the positive predictive value was 90.77 % （59/65）,and negative predictive value was 92.86 % （52/56）.Conclusions Breast cancer patients have a high incidence of anxiety.SELDI technology has showed high sensitivity and specificity in anxiety detecting.As an objective assessment tool,it could have better prospects for clinical use.